Citations

Mayo Clinic

Showing 10 of 108551 citations.

Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care
Rowan, Courtney M. , Zambrano, Laura D. , Newhams, Margaret M. , Kücükak, Suden, McNamara, Elizabeth R, Mack, Elizabeth H. , Fitzgerald, Julie C. , Irby, Katherine , Schuster, Jennifer E. , Kong, Michele, Loftis, Laura L. , Kolmar, Amanda , Babbitt, Christopher , Nofziger, Ryan A. , Hall, Mark W. , Gertz, Shira J. , Zinter, Matt S. , Halasa, Natasha , Bradford, Tamara T. , McLaughlin, Gwenn E., Singh, Aalok R. , Staat, Mary Allen , Coates, Bria M. , Crandall, Hillary R, Maamari, Mia , Havlin, Kevin , Schwarz, Adam J. , Carroll, Christopher L. , Levy, Emily R. , Campbell, Angela P. , Randolph, Adrienne G. , Chou, Janet , Investigators, Overcoming COVID-19, Kong, Michele, Gaspers, Mary Glas , Sanders, Ronald C., Schwarz, Adam J, Harvey, Helen , Port, Emily, Shankman, Sara, Mansour, Rachel, Espinal, Paula S., Tarquinio, Keiko M. , Bhoojhawon, Guru , Sullivan, Janice E, Bradford, Tamara T, Newhams, Margaret M, Chen, Sabrina , Young, Cameron C, Carroll, Ryan W. , Yager, Phoebe H. , Flori, Heidi R. , Johnson, Brandi A., Drapeau, Noelle M., Malloch, Lacy , Martin, Lora, McGraw, Sarah , Schuster, Jennifer E, Cullimore, Melissa L. , Clouser, Katharine N. , Kleinman, Lawrence C. , Horwitz, Steven M. , Kuebler, Joseph D. , Soma, Vijaya L, Doymaz, Sule , Schwartz, Stephanie P, Walker, Tracie C. , Lansell, Amanda , Hall, Mark W. , Burnett, Ryan H., Bush, Jenny L., Carcillo, Joseph A. , Butler, Andrew , Reed, Nelson, Stewart, Laura S , Golchha, Meena, Samperio, Marian, Qurashi, Jacob , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Kong, Michele , Martin, Lora , Randolph, Adrienne G , Levy, Emily R , Kong, Michele , Staat, Mary A , Gertz, Shira J , LaBere, Brenna , Young, Cameron C. , Maddux, Aline B. , Kong, Michele, Dapul, Heda , Schwartz, Stephanie P. , Bembea, Melania M. , Cvijanovich, Natalie Z , Hobbs, Charlotte V. , Wellnitz, Kari , Moffitt, Kristin , Investigators, Overcoming COVID-19, Kong, Michele, Typpo, Katri , Schwarz, Adam J, Pannaraj, Pia S. , Giuliano, John S. , Michelson, Kelly Nicole , Sullivan, Janice E, Montgomery, Vicki , Bradford, Tamara T, Graciano, Ana Lía , Newhams, Margaret M, Young, Cameron C, Son, Mary Beth F. , Fernandes, Neil D. , Hume, Janet R. , Behl, Supriya , McGraw, Sarah, Schuster, Jennifer E, Spinella, Philip C. , McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , BIAGAS, KATHERINE V. , Schwartz, Stephanie P, Shein, Steven L. , Bush, Jenny, Thomas, Neal J. , Fink, Ericka L. , Reed, Nelson, Muñoz, Álvaro Coronado , McGuire, John K.

Clinical Infectious Diseases | March 11, 2024 | Volume: 79 | Issue: 2 | Pages: 395-404

10.1093/cid/ciae133 | PMID 38465976 Get It

Abstract Background We aimed to determine if pre-existing immunocompromising conditions (ICCs) were associated with the presentation or outcome of patients with acute coronavirus disease 2019 (COVID-19) admitted for pediatric intensive care. Methods Fifty-five hospitals in 30 US states reported cases through the Overcoming COVID-19 public health surveillance registry. Patients <21 years admitted 12 March 2020–30 December 2021 to the pediatric intensive care unit (PICU) or high-acuity unit for acute COVID-19 were included. Results Of 1274 patients, 105 (8.2%) had an ICC, including 33 (31.4%) hematologic malignancies, 24 (22.9%) primary immunodeficiencies and disorders of hematopoietic cells, 19 (18.1%) nonmalignant organ failure with solid-organ transplantation, 16 (15.2%) solid tumors, and 13 (12.4%) autoimmune disorders. Patients with ICCs were older, had more underlying renal conditions, and had lower white blood cell and platelet counts than those without ICCs, but had similar clinical disease severity upon admission. In-hospital mortality from COVID-19 was higher (11.4% vs 4.6%, P = .005) and hospitalization was longer (P = .01) in patients with ICCs. New major morbidities upon discharge were not different between those with and without ICC (10.5% vs 13.9%, P = .40). In patients with ICCs, bacterial coinfection was more common in those with life-threatening COVID-19. Conclusions In this national case series of patients <21 years of age with acute COVID-19 admitted for intensive care, existence of a prior ICCs were associated with worse clinical outcomes. Reassuringly, most patients with ICCs hospitalized in the PICU for severe acute COVID-19 survived and were discharged home without new severe morbidities.
Oblique anterior column realignment with a mini-open posterior column osteotomy for minimally invasive adult spinal deformity correction: illustrative case
Pennington, Zach , Brown, Nolan J. , Pishva, Seyedamirhossein , Pham, Martin H. , Pennington, Zach , González, Hernán F. J.

Journal of Neurosurgery: Case Lessons | March 11, 2024 | Volume: 7 | Issue: 11 | Pages: No page available

10.3171/case23680 | PMID 38467047 Get It

BACKGROUND Adult spinal deformity (ASD) occurs from progressive anterior column collapse due to disc space desiccation, compression fractures, and autofusion across disc spaces. Anterior column realignment (ACR) is increasingly recognized as a powerful tool to address ASD by progressively lengthening the anterior column through the release of the anterior longitudinal ligament during lateral interbody approaches. Here, we describe the application of minimally invasive ACR through an oblique antepsoas corridor for deformity correction in a patient with adult degenerative scoliosis and significant sagittal imbalance. OBSERVATIONS A 65-year-old female with a prior history of L4–5 transforaminal lumbar interbody fusion and morbid obesity presented with refractory, severe low-back and lower-extremity pain. Preoperative radiographs showed significant sagittal imbalance. Computed tomography showed a healed L4–5 fusion and a vacuum disc at L3–4 and L5–S1, whereas magnetic resonance imaging was notable for central canal stenosis at L3–4. The patient was treated with a first-stage L5–S1 lateral anterior lumbar interbody fusion with oblique L2–4 ACR. The second-stage posterior approach consisted of a robot-guided minimally invasive T10–ilium posterior instrumented fusion with a mini-open L2–4 posterior column osteotomy (PCO). Postoperative radiographs showed the restoration of her sagittal balance. There were no complications. LESSONS Oblique ACR is a powerful minimally invasive tool for sagittal plane correction. When combined with a mini-open PCO, substantial segmental lordosis can be achieved while eliminating the need for multilevel PCO or invasive three-column osteotomies.
Role of stereotactic radiosurgery for recurrent skull base acinic cell carcinoma: illustrative case
Yoshihira, Tomohiro, Umekawa, Motoyuki , Shinya, Yuki , Hasegawa, Hirotaka , Shin, Masahiro , Kikuchi, Yodai, Saito, Yuki , Katano, Atsuto , Shinya, Yuki , Kondo, Kenji , Shinozaki‐Ushiku, Aya , Saito, Nobuhito

Journal of Neurosurgery: Case Lessons | March 11, 2024 | Volume: 7 | Issue: 11 | Pages: No page available

10.3171/case2476 | PMID 38467040 Get It

BACKGROUND Acinic cell carcinomas (AcCCs), rare malignancies of the salivary glands, often recur and metastasize, particularly in the skull base. Conventional radical resection can be invasive for skull base AcCCs adjacent to cranial nerves and major vasculature, and the effectiveness of stereotactic radiosurgery (SRS) as an alternative is not well established. OBSERVATIONS This case report details the application of SRS for recurrent skull base AcCCs. A 71-year-old male with a history of resection for a right mandibular AcCC 23 years earlier experienced tumor recurrence involving the right cavernous sinus and nasal cavity. He underwent endoscopic transnasal surgery followed by SRS targeting different tumor locations—the cavernous sinus to the pterygopalatine fossa, maxillary sinus, and clivus—each with a prescribed dose of 20 Gy to the 40% to 50% isodose line. After the first skull base metastasis, additional sessions of localized SRS after endoscopic surgery led to a 12-year survival without sequela. LESSONS This is a report indicating that SRS for skull base AcCCs can achieve favorable local control, functional preservation, and long-term survival. SRS may be suitable for skull base AcCC given the lesion’s tendency toward multiple local recurrences. Further investigation is needed to validate the treatment’s efficacy.
Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles
Mangioris, Georgios , Lennon, Vanda A. , Chang, Bryce Kalei , Dubey, Divyanshu , Dyck, P. James B. , McKeon, Andrew, Mills, John R. , Pittock, Sean J. , Ζεκερίδου, Αναστασία , Pittock, S J , Chang, Bryce K , Flanagan, E P , Zekeridou, Anastasia , Dubey, Divyanshu , Hálfdánarson, Þorvarður R. , Flanagan, Eoin P. , McKeon, Andrew

European Journal of Neurology | March 11, 2024 | Volume: 31 | Issue: 6 | Pages: No page available

10.1111/ene.16273 | PMID 38466015 Get It

AbstractBackground and purposeParaneoplastic neurological autoimmunity is well described with small‐cell lung cancer, but information is limited for other neuroendocrine neoplasms (NENs).MethodsAdult patients with histopathologically confirmed non‐pulmonary NENs, neurological autoimmunity within 5 years of NEN diagnosis, and neural antibody testing performed at the Mayo Clinic Neuroimmunology Laboratory (January 2008 to March 2023) were retrospectively identified. Control sera were available from patients with NENs without neurological autoimmunity (116).ResultsThirty‐four patients were identified (median age 68 years, range 31–87). The most common primary tumor sites were pancreas (nine), skin (Merkel cell, eight), small bowel/duodenum (seven), and unknown (seven). Five patients received immune checkpoint inhibitor (ICI) therapy before symptom onset; symptoms preceded cancer diagnosis in 62.1% of non‐ICI‐treated patients. The most frequent neurological phenotypes (non‐ICI‐treated) were movement disorders (12; cerebellar ataxia in 10), dysautonomia (six), peripheral neuropathy (eight), encephalitis (four), and neuromuscular junction disorders (four). Neural antibodies were detected in 55.9% of patients studied (most common specificities: P/Q‐type voltage‐gated calcium channel [seven], muscle‐type acetylcholine receptor [three], anti‐neuronal nuclear antibody type 1 [three], and neuronal intermediate filaments [two]), but in only 6.9% of controls. Amongst patients receiving cancer or immunosuppressive therapy, 51.6% had partial or complete recovery. Outcomes were unfavorable in 48.3% (non‐ICI‐treated) and neural autoantibody positivity was associated with poor neurological outcome.DiscussionNeurological autoimmunity associated with non‐pulmonary NENs is often multifocal and can be treatment responsive, underscoring the importance of rapid recognition and early treatment.
CD74 Promotes Cyst Growth and Renal Fibrosis in Autosomal Dominant Polycystic Kidney Disease
Zhou, Julie , Cheng, Alice, Li, Xiaoyan , Agborbesong, Ewud , Harris, Peter C. , Zhou, Julie Xia, Cheng, Alice Shasha, Li, Linda Xiaoyan , Harris, Peter C , Chen, Li , Torres, Vicente E. , Li, Xiaogang

Cells | March 11, 2024 | Volume: 13 | Issue: 6 | Pages: 489

10.3390/cells13060489 | PMID 38534333 Get It

The progression of autosomal dominant polycystic kidney disease (ADPKD), an inherited kidney disease, is associated with renal interstitial inflammation and fibrosis. CD74 has been known not only as a receptor of macrophage migration inhibitory factor (MIF) it can also have MIF independent functions. In this study, we report unknown roles and function of CD74 in ADPKD. We show that knockout of CD74 delays cyst growth in Pkd1 mutant kidneys. Knockout and knockdown of CD74 (1) normalize PKD associated signaling pathways, including ERK, mTOR and Rb to decrease Pkd1 mutant renal epithelial cell proliferation, (2) decrease the activation of NF-κB and the expression of MCP-1 and TNF-alpha (TNF-α) which decreases the recruitment of macrophages in Pkd1 mutant kidneys, and (3) decrease renal fibrosis in Pkd1 mutant kidneys. We show for the first time that CD74 functions as a transcriptional factor to regulate the expression of fibrotic markers, including collagen I (Col I), fibronectin, and α-smooth muscle actin (α-SMA), through binding on their promoters. Interestingly, CD74 also regulates the transcription of MIF to form a positive feedback loop in that MIF binds with its receptor CD74 to regulate the activity of intracellular signaling pathways and CD74 increases the expression of MIF in ADPKD kidneys during cyst progression. We further show that knockout of MIF and targeting MIF with its inhibitor ISO-1 not only delay cyst growth but also ameliorate renal fibrosis through blocking the activation of renal fibroblasts and CD74 mediated the activation of TGF-β-Smad3 signaling, supporting the idea that CD74 is a key and novel upstream regulator of cyst growth and interstitial fibrosis. Thus, targeting MIF-CD74 axis is a novel therapeutic strategy for ADPKD treatment.
Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy
Arnaldi, Dario , Mattioli, Pietro , Raffa, Stefano, Pardini, Matteo , Massa, Federico , Iranzo, Álex , Perissinotti, Andrés , Gaig, Carles , Serradell, Mónica , Muñoz‐Lopetegi, Amaia , Mayà, Gerard , Liguori, Claudio , Fernandes, Mariana , Miyagawa, Toji , Lowe, Val J. , Puligheddu, Monica , Serra, Alessandra , Hu, Michele T., Klein, Johannes , Bes, Frédérik , Kunz, Dieter , Verbizier, Delphine de, Kulcsárová, Kristína , Giuliani, Alessandro , Pagani, Marco , Group, International REM Sleep Behavior Disorder Study, Liguori, Claudio , Miyamoto, Tomoyuki , Kunz, Dieter , Antelmi, Elena , Terzaghi, Michele , Massa, Federico , Maya, Gerard , Puligheddu, Monica , Kulcsarova, Kristina , Mattioli, Pietro , Arnaldi, Dario , Niñerola‐Baizán, Aida , Gaig, Carles , Placidi, Fabio , Chiaravalloti, Agostino , Šonka, Karel , Dušek, Petr , Zogala, David , Trnka, Jiří , Boeve, Bradley F. , Miyamoto, Tomoyuki , Miyamoto, Masayuki , Figorilli, Michela , Hu, Michele T., Cochen De Cock, Valérie , Plazzi, Giuseppe , Antelmi, Elena , Bossert, Irene , Martino, Alessio , Nobili, Flavio Mariano , Morbelli, Silvia , Group, International REM Sleep Behavior Disorder Study

Annals of Neurology | March 11, 2024 | Volume: 95 | Issue: 6 | Pages: 1178-1192

10.1002/ana.26902 | PMID 38466158 Get It

Objective To apply a machine learning analysis to clinical and presynaptic dopaminergic imaging data of patients with rapid eye movement (REM) sleep behavior disorder (RBD) to predict the development of Parkinson disease (PD) and dementia with Lewy bodies (DLB). Method s In this multicenter study of the International RBD study group, 173 patients (mean age 70.5 ± 6.3 years, 70.5% males) with polysomnography‐confirmed RBD who eventually phenoconverted to overt alpha‐synucleinopathy (RBD due to synucleinopathy) were enrolled, and underwent baseline presynaptic dopaminergic imaging and clinical assessment, including motor, cognitive, olfaction, and constipation evaluation. For comparison, 232 RBD non‐phenoconvertor patients (67.6 ± 7.1 years, 78.4% males) and 160 controls (68.2 ± 7.2 years, 53.1% males) were enrolled. Imaging and clinical features were analyzed by machine learning to determine predictors of phenoconversion. Results Machine learning analysis showed that clinical data alone poorly predicted phenoconversion. Presynaptic dopaminergic imaging significantly improved the prediction, especially in combination with clinical data, with 77% sensitivity and 85% specificity in differentiating RBD due to synucleinopathy from non phenoconverted RBD patients, and 85% sensitivity and 86% specificity in discriminating PD‐converters from DLB‐converters. Quantification of presynaptic dopaminergic imaging showed that an empirical z ‐score cutoff of −1.0 at the most affected hemisphere putamen characterized RBD due to synucleinopathy patients, while a cutoff of −1.0 at the most affected hemisphere putamen/caudate ratio characterized PD‐converters. Interpretation Clinical data alone poorly predicted phenoconversion in RBD due to synucleinopathy patients. Conversely, presynaptic dopaminergic imaging allows a good prediction of forthcoming phenoconversion diagnosis. This finding may be used in designing future disease‐modifying trials. ANN NEUROL 2024;95:1178–1192
Thrombolysis Is Not Indicated for Minor Strokes If They Are Truly Nondisabling
Braksick, Sherri A. , Rabinstein, Alejandro A. , Rabinstein, Alejandro A

Stroke | March 11, 2024 | Volume: 55 | Issue: 4 | Pages: 893-894

10.1161/strokeaha.124.046549 | PMID 38465619 Get It

Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
Allen, Alina M. , Charlton, Michael , Cusi, Kenneth , Harrison, Stephen A. , Kowdley, Kris V. , Noureddin, Mazen , Shubrook, Jay H , Allen, Alina M

Postgraduate Medicine | March 11, 2024 | Volume: 136 | Issue: 3 | Pages: 229-245

10.1080/00325481.2024.2325332 | PMID 38465573 Get It

Prokinetics‐safety and efficacy: The European Society of Neurogastroenterology and Motility/The American Neurogastroenterology and Motility Society expert review
Bor, Serhat , Kalkan, İsmail Hakkı , Savarino, Edoardo , Rao, Satish S.C. , Tack, Jan , Pasricha, Jay, Cangemi, David J. , Schol, Jolien , Karunaratne, Tennekoon B. , Ghisa, Matteo , Ahuja, Nitin K. , Lacy, Brian E. , Kalkan, İsmail H , Rao, Satish , Cangemi, David , Karunaratne, Tennekon , Lacy, Brian , Tack, Jan , Bor, Serhat , Savarino, Edoardo , Pasricha, Jay, Lacy, Brian E.

Neurogastroenterology & Motility | March 11, 2024 | Volume: 36 | Issue: 5 | Pages: No page available

10.1111/nmo.14774 | PMID 38462678 Get It

AbstractBackgroundProkinetics are a class of pharmacological drugs designed to improve gastrointestinal (GI) motility, either regionally or across the whole gut. Each drug has its merits and drawbacks, and based on current evidence as high‐quality studies are limited, we have no clear recommendation on one class or other. However, there remains a large unmet need for both regionally selective and/or globally acting prokinetic drugs that work primarily intraluminally and are safe and without systemic side effects.PurposeHere, we describe the strengths and weaknesses of six classes of prokinetic drugs, including their pharmacokinetic properties, efficacy, safety and tolerability and potential indications.
First‐in‐man report of transsubclavian venous implantation of the Aveir leadless cardiac pacing system
Ward, Robert C. , Amin, Hina , Noseworthy, Peter A. , Asirvatham, Samuel J. , Friedman, Paul A. , Mulpuru, Siva K. , Balanescu, Dinu V , Ward, Robert C , Noseworthy, Peter A , Asirvatham, Samuel J , Friedman, Paul A , Mulpuru, Siva K , Balanescu, Dinu Valentin

Journal of Cardiovascular Electrophysiology | March 11, 2024 | Volume: 35 | Issue: 5 | Pages: 1041-1045

10.1111/jce.16241 | PMID 38462703 Get It

Abstract Introduction Transsubclavian venous implantation of the Aveir leadless cardiac pacemaker (LCP) has not been previously reported. Methods and Results Three cases of transsubclavian implantation of the Aveir LCP are reported. Two cases were postbilateral orthotopic lung transplant, without appropriate femoral or jugular access due to recent ECMO cannulation and jugular central venous catheters. In one case, there was strong patient preference for same‐day discharge. Stability testing confirmed adequate fixation and electrical testing confirmed stable parameters in all cases. All patients tolerated the procedure well without significant immediate complications. Conclusions We demonstrate the feasibility of transsubclavian implantation of the Aveir LCP.